Biote Corp. Delivers Strong 2025 Results and Outlines Strategic 2026 Priorities

Biote Corp. (NASDAQ: BTMD), a recognized leader in hormone optimization and therapeutic wellness, has released its full-year 2025 financial results, provided guidance for 2026, and outlined several significant developments that investors must closely review. The company’s latest presentation showcases robust performance, strategic acquisitions, and a clear path toward expanding its addressable market, all of which have potential implications for the company’s share price.

Key Financial Highlights for 2025

• Revenue: \$192.2 million for 2025.
• Adjusted EBITDA: \$53.5 million, representing an Adjusted EBITDA Margin of 27.8%.
• Net Income: \$31.6 million, translating to a 16.4% net income margin.
• Active Patients: Approximately 400,000, with nearly 6 million procedures performed.
• Biote-Certified Practitioners: Over 9,200 practitioners, forming the largest clinic network in the country.

2026 Guidance and Strategic Priorities

• Revenue Guidance: The company expects revenue to remain above \$190 million in 2026, with Adjusted EBITDA projected above \$38 million.
• Biote plans to intensify efforts to add new practitioners and leverage its enhanced clinical decision support software to drive value for providers and patients.
• Focus on expanding differentiated offerings and maximizing the productivity of its commercial organization.
• Ample capacity to accelerate growth among newly trained practitioners via a “quickstart” program.
• Positioning Biote to serve a broader range of physicians beyond early adopters of its method.
• Commitment to implementing strategic changes rapidly, with anticipated improvement in commercial productivity later in 2026.

Strategic Acquisitions and Capital Allocation

• Vertical Integration: Recent strategic acquisition strengthens Biote’s control over its supply chain, enhances efficiency, and enables longer-term development of innovative wellness therapeutics. This vertical integration is expected to drive margin improvement and support new product research.
• Share Repurchase Program:
  • Repurchased approximately 5.5 million shares of Class V voting stock for \$25.1 million.
  • Executed further repurchases: 2.8 million shares for \$12.5 million, and 6.1 million shares for \$18.5 million paid in January 2026.
  • Repurchased \$3.4 million of Class A common stock in 2025, with \$11 million remaining in the program.

Business Model and Market Opportunity

• Biote operates a capital-light, highly scalable business model leveraging proprietary technology, clinical education, and training platforms.
• Significant white-space opportunity with 260,000 U.S. practitioners in relevant specialties, compared to 9,200 currently certified by Biote.
• Biote-branded nutraceuticals and cosmeceuticals supplement core hormone therapy offerings, strengthening patient and clinic loyalty and enhancing practitioner economics.
• Expansion into wellness solutions such as weight loss, body composition, sexual health, preventive health, hair loss, and aesthetic dermatology—addressing large, growing markets with increasing consumer demand for evidence-based wellness solutions.

Research, Regulatory, and Litigation Updates

• Biote continues to be a leading voice in clinical research, education, and training, with published studies in peer-reviewed journals demonstrating the safety and efficacy of its hormone optimization therapies.
• Maintains national and regional training centers, employing a robust clinical faculty to ensure high standards and practitioner competency.
• 2025 restructuring costs included a \$1.3 million inventory impairment charge related to a voluntary recall of select lots of hormone pellets, executive severance costs of \$1.2 million, and \$0.4 million in consulting/legal fees for CEO transition.
• Ongoing and former owner litigation expenses are detailed in reconciliation, but appear largely settled with the completion of share repurchase agreements and related payments.

What Investors Should Watch

• Potential Share Price Movers:
  • Continued strong financial performance and profitability with substantial margins.
  • Material progress in strategic acquisitions, vertical integration, and product innovation expected to enhance long-term profitability.
  • Large-scale share repurchases, which reduce share count and could be accretive to EPS.
  • Geographic and practitioner network expansion, unlocking significant market opportunity.
  • Ability to leverage new technology and expand into adjacent wellness markets.
  • Management’s confidence in executing on growth strategies, despite anticipated time lag for results to materialize.
• Risks and Uncertainties:
  • Business is subject to regulatory, competitive, and economic risks, including the impact of recalls, litigation, macroeconomic conditions, and changes in laws.
  • Forward-looking projections are subject to uncertainty, and actual results may differ materially.

Conclusion

Biote Corp. emerges from 2025 with robust growth, profitability, and a clear vision for the future. Its strategic investments in vertical integration, practitioner expansion, and platform innovation position the company to capture a larger share of the \$400 billion therapeutic wellness market. The company’s capital allocation and share repurchase activities further signal management’s confidence in long-term value creation. Investors should closely monitor execution against 2026 priorities, ongoing margin improvements, and the pace of geographic and practitioner network expansion.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks, uncertainties, and assumptions. Investors are encouraged to review the company’s filings and consult with their financial advisor before making investment decisions.

View biote Corp. Historical chart here